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Existing pharmacokinetic monitoring tools for cyclosporine fail to correlate with clinical
response. In dogs, pharmacodynamic monitoring of nuclear factor of activated T cell (NFAT)
regulated cytokines is thought to provide a better overall evaluation of the immune response to
cyclosporine than blood levels; however, such monitoring tools are not available in cats. In this
study, we designed and optimized a protocol for maximal T lymphocyte stimulation in cats. This
is the first step in the development of a pharmacodynamic monitoring tool for cyclosporine in
cats based on expression of NFAT-regulated cytokines. We also confirmed that cyclosporine has
anti-lymphocytic properties in cats, and we were the first to document induction of apoptosis by
cyclosporine in cats. Differences in individual patient response to cyclosporine may be
influenced by apoptotic response of lymphocytes to cyclosporine. Additional studies are
required to optimize and validate polymerase chain reaction monitoring of NFAT-regulated
cytokines for cyclosporine-mediated immunosuppression.
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CHAPTER I
LITERATURE REVIEW
Background
Cyclosporine is a fat-soluble, hydrophobic polypeptide derived from the fungus
Beauvaria nivea1,2. Cyclosporine was discovered in 1971 as part of a screening program of
fungal metabolites for immunosuppressive activity, and was subsequently purified, with initial
studies published in 19763,4. Cyclosporine was welcomed by the research community and was
investigated as a potential drug in the prevention of organ transplant rejection. Studies in rats
documented that cyclosporine could prolong heart allograft acceptance, and further studies in
pigs and dogs evaluated its use in orthotopic heart grafts and renal allografts, respectively3,5,6.
Cyclosporine was approved by the Food and Drug Administration (FDA) in 1983 and has
subsequently become a cornerstone of immunosuppression in transplantation medicine7,8.
Although the vast majority of early work occurred in humans, dogs and laboratory animals,
Latimer and colleagues evaluated the effects of cyclosporine in cats in 19869. In this study, oral
cyclosporine administration resulted in moderate to marked variation in trough cyclosporine
concentrations between cats, and there was no correlation between serum cyclosporine
concentration and lymphocyte transformation9. This highlighted the significance of cat-to-cat
variation in response to cyclosporine. In 2011, the FDA approved a modified cyclosporine oral
suspension for the management of feline allergic dermatitis. Despite being approved only for use
in hypersensitivity dermatitis, similar to in dogs, this feline cyclosporine suspension is finding
1

off-label use for a large number of dermatological and systemic inflammatory conditions in cats.
Unfortunately, optimal dosing protocols for achieving immunosuppression with cyclosporine in
cats remain unclear and methods that objectively monitor effectiveness of immunosuppression
have not been established. Ideally, effectiveness of immunosuppression should be individually
monitored to ensure that the patient is truly immunosuppressed, and that the cyclosporine is
effectively treating the condition.
Mechanisms of Action of Cyclosporine
Immunosuppressive Effects
In the absence of cyclosporine, antigen in conjunction with major histocompatibility
complex binds to the T-cell receptor (TCR) on the surface of a T lymphocyte. Binding to the
TCR results in an increase in intracellular calcium. This increase in intracellular calcium causes
activation of calcineurin. Calcineurin is an intracellular protein phosphatase that activates gene
transcription factors via dephosphorylation of the cytoplasmic form of nuclear factor of activated
T cells (NFAT)10. Once dephosphorylated, the activated NFAT migrates into the nucleus, where
it upregulates transcription of genes coding for many cytokines, including interleukin-2 (IL-2),
interleukin-4 (I-4), interleukin-5 (IL-5), interleukin-13 (IL-13), granulocyte-macrophage colony
stimulating factor (GM-CSF), tumor necrosis factor α (TNF-α) and interferon-γ (IFN-γ) 11
Cyclosporine acts as a calcineurin inhibitor. Cyclosporine passes into the cytoplasm of the T
lymphocyte and binds cyclophilin A, a chaperone protein. The cyclosporine-cyclophilin A
complex has a high affinity for calcineurin, inhibiting its activation10. This ultimately prevents
upregulation of NFAT-regulated genes and reduces cytokine production, in particular IL-21. In
T-lymphocytes, IL-2 binds to the IL-2 receptor, leading to down-stream signal processing,
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activation and proliferation of T lymphocytes12. Thus, blocking IL-2 production reduces
lymphocyte proliferation.
Anti-inflammatory Effects
Cyclosporine has two primary mechanisms of action in inflammatory dermatological
disease. Firstly, it decreases cytokine production by inflammatory infiltrates and, secondly, it
inhibits the epidermal cytokine network21. In addition to its effects on lymphocytes, cyclosporine
has also been shown to have anti-inflammatory effects on basophils, mast cells, macrophages,
eosinophils, neutrophils, keratinocytes, and endothelial cells16,21–35. These mechanisms
contribute to its anti-inflammatory properties
Anti-proliferative Effects
Cyclosporine has been shown to inhibit proliferation of keratinocytes at the G0 and G1
phases of the cell cycle; however, it is not known if these effects are clinically relevant, as the
doses required may not be achievable in vivo 1,36
Other Effects
Cyclosporine is extensively utilized in veterinary ophthalmology, primarily for treatment
of immune-mediated keratoconjunctivitis sicca (KCS) in dogs, although its safety and efficacy
have not been prospectively evaluated in cats with KCS37. A 2009 retrospective study did
however document the successful use of a topical 1.5% cyclosporine solution in the management
of proliferative feline eosinophilic keratitis, and a subsequent article also documented successful
use of a topical cyclosporine solution in cats that failed to respond to topical corticosteroids38,39.
Cyclosporine’s lacrimometic effects are mediated via anti-prolactin receptor activity14.
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Cyclosporine has also been shown to have anti-parasitic properties; however, it is unlikely to be
used clinically to control parasitic infections1
Pharmacokinetics
Absorption
Following oral administration, cyclosporine is absorbed across the intestinal epithelium
via passive diffusion. As cyclosporine is a P-glycoprotein substrate, its intestinal absorption is
limited via efflux pumps40. The licensed formulation for cyclosporine in cats is a microemulsion,
and other non-microemulsified formulations such as Sandimmune (Novartis Pharmaceuticals)
are no longer routinely used41. Sandimmune has poor and highly variable oral bioavailability in
humans, and is therefore not recommended in veterinary species2. The estimated oral
bioavailability of the microemulsion formulation of cyclosporine in cats is 29% after 7 days of
administration, and 25% after 14 days of administration42. Oral bioavailability does not appear to
be affected by food, unlike in dogs43,44. In addition, ocular, transdermal and subcutaneous
administration have been studied in cats. Ocular and transdermal administration of cyclosporine
is reported to result in inconsistent absorption, whereas subcutaneous administration appears to
be efficacious in a study evaluating alternate day dosing in the management of feline allergic
dermatitis 45–47.
Distribution
Following oral absorption, cyclosporine is distributed widely, and accumulates in the skin
and adipose tissue48,49. The volume of distribution is reported to be 1.71 L/kg following
intravenous administration, and 5.95 L/kg following oral administration42. Peak blood
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concentrations occur within 1-2 hours of oral administration of cyclosporine in cats, and peak
concentrations are highly variable amongst cats, with a coefficient of variation of 31%42.
Metabolism
The major sites of cyclosporine metabolism are the liver and, to a lesser extent, the small
intestines and kidneys50. Cyclosporine is a known substrate of cytochrome P-450 3A in humans,
and feline responses to ketoconazole, itraconazole and clarithromycin suggest that this may also
be true in cats51–53. Hepatic metabolism of cyclosporine is primarily via N-demethylation and
hydroxylation of amino acid residues54. M-21 is the primary N-demethylated cyclosporine
metabolite, whereas M-1 and M-17 are the primary hydroxy metabolites of cyclosporine55. The
composition of cyclosporine metabolites is important, as metabolites such as M-17 have in vitro
immunosuppressive activities, and their concentration can exceed that of the parent drug56. In
cats, the concentrations of cyclosporine metabolites differ from in dogs, with cats having
approximately equal concentrations of M-17, M-1 and M-2155. In contrast, dogs have lower
levels of M-17 relative to other metabolites55.
Cyclosporine metabolism can be influenced by drugs that induce or inhibit cytochrome
P450 enzyme systems. Although a large amount of research has been performed in this area,
little research has been performed specific to cats, and many potential drug interactions are
inferred from other species. In 2007, Shah et al. investigated cytochrome P450-mediated drug
metabolism in cats and noted that sexual differences were present in the activity levels of
cytochrome P450 (CYP)2D and CYP3A, with CYP2D being higher in females and CYP3A
being higher in male cats57. This research suggests that different doses of CYP2D and CYP3A
drugs may be required in male and female cats. Interestingly, the rate of elimination of CYP3A
substrates in female cats was similar to that in people, whereas the rate in male cats was more
5

similar to dogs57. Ketoconazole is an azole antifungal medication which inhibits CYP3A58.
Concurrent administration of ketoconazole with cyclosporine has been shown to inhibit
metabolism of cyclosporine and increase blood cyclosporine levels; this combination may be
used for clinical benefit51,59–63. In cats, ketoconazole administration results in a 1.8-2.2 fold
increase in blood cyclosporine levels, and an approximately 60% reduction in systemic clearance
rate51. A 2009 study evaluated the effect of ketoconazole on feline hepatic microsomes and
CYP3A activities, via evaluation of midazolam 1’ and 4-hydroxylation. In this study, it was
noted that ketoconazole was effective in inhibiting feline hepatic CYP3A activity, albeit to a
much lesser extent than occurred in either humans and dogs64. In the same study, cimetidine and
erythromycin did not affect CYP3A activity in cats64. Despite the differences between cats and
other species with regard to effect of azole drugs on CYP3A activity, both itraconazole and
ketoconazole have been shown to result in significant increases in cyclosporine blood levels in
cats51,52. In addition, clarithromycin was recently studied as a potential agent to reduce both the
dose and frequency of cyclosporine in feline transplant patients. In the study, clarithromycin
administration resulted in a 65% reduction in the dose of cyclosporine required to reach a predetermined trough cyclosporine level; it also allowed for once daily administration of
cyclosporine due to the increased half-life of cyclosporine when combined with clarithromycin53.
Excretion
Cyclosporine has an elimination half-life of 8 hours in cats, and its metabolites are
excreted through the biliary system, with minimal renal excretion41,42,50,65.
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Licensed Indications
Cyclosporine is the only FDA-approved immunosuppressive agent in cats. It is licensed
as a microemulsion formulation (Atopica®) for the management of feline allergic dermatitis.
Atopica® is approved for cats of at least 6 months of age and weighing at least 1.4kg66.
According to the manufacturer, Atopica® should be used with caution in patients with diabetes
mellitus or renal insufficiency66. The recommended dose is 7mg/kg orally every 24 hours, until
resolution of clinical signs, followed by a taper50.
Other Dermatological Uses
A retrospective case study, published in 2012, revealed that modified cyclosporine was
effective in the management of pemphigus foliaceus in cats, and had a glucocorticoid-sparing
effect67. Additional literature on cyclosporine in feline dermatology is limited to case reports or
case series and, as such, caution should be advised when applying the data to larger populations
of animals. Case reports and case series document the use of cyclosporine in feline lymphocytic
mural folliculitis, feline urticaria pigmentosa, idiopathic facial dermatitis, plasma cell
pododermatitis and pseudopelade68–72. Over time, it is likely that cyclosporine usage in feline
dermatology will increase due to its reported clinical efficacy and favorable toxicity profile.
Renal Transplantation
Preliminary studies into renal allografts in dogs and cats revealed that a combination of
prednisolone and cyclosporine could be effective in the management of renal transplants, given
appropriate patient selection73. These early studies also stressed the importance of pharmacologic
and immunologic monitoring of renal transplantations, and subsequent individual dose
adjustments in therapy73. Following these initial reports a case study was published that
7

documented survival of a 6-year Persian cat for greater than 18 months with a renal transplant
from an unrelated donor, further prompting additional research into the use of prednisolone and
cyclosporine for immunosuppression in transplant recipients 74. Over time, the number of
patients receiving a combination of prednisolone and cyclosporine increased, and a large
retrospective study on feline renal transplants was published in 2008. In this paper, 77.5% of
patients with a renal transplant survived to hospital discharge and the median survival time was
almost 2 years75. In the study, however, 37% of cases developed an infection posttransplantation. The high prevalence of infection in renal transplant patients despite attempts to
monitor trough cyclosporine levels indicates the need for further research into alternative
monitoring tools for cyclosporine in cats.
Systemic Inflammatory Diseases
Cyclosporine has been used off-label in a number of systemic inflammatory conditions,
including asthma, hematological disorders, inflammatory bowel disease and chronic progressive
polyarthritis. Dosages used in feline systemic inflammatory diseases vary widely (Table 1.1).
Cyclosporine has been studied extensively in feline asthma. In vitro airway hyperresponsiveness and eosinophil yield were reduced in bronchoalveolar lavage fluid (BAL)
following treatment with cyclosporine in chronically antigen-challenged cats76. Clinicians have
subsequently utilized cyclosporine in cases where glucocorticoids were contraindicated. One
such case report documented the use of cyclosporine in a cat with asthma which could not
receive steroid medication due to concurrent diabetes mellitus and congestive heart failure77.
Cyclosporine is a promising medication in the management of feline asthma in cases where
concurrent disease limits steroid use. Cyclosporine has also been documented in the management
of feline pure red cell aplasia78–80, immune-mediated thrombocytopenia81, idiopathic
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inflammatory bowel disease82,83 and chronic progressive polyarthritis84. Cyclosporine is typically
considered in these conditions when glucocorticoids alone are insufficient to induce disease
remission or when steroids are otherwise contra-indicated. Anecdotally, some clinicians are also
using cyclosporine as a second immunosuppressive agent in patients that cannot tolerate
glucocorticoid side effects, thus allowing for a more rapid taper in glucocorticoid dose
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Table 1.1

Starting doses of cyclosporine in feline systemic inflammatory diseases
Disease

Paper
Nafe and Leach, 2015
Stokol and Blue, 1999
Garon et al., 1999

Cyclosporine
Dose
4mg/kg
20mg/kg
5mg/kg

Dose
Frequency
PO q 12h
PO q 24h
PO q 12h

Feline Asthma
Pure Red Cell Aplasia
Immune-Mediated
Thrombocytopenia
Inflammatory Bowel Disease
Chronic Progressive Polyarthritis

Jergens, 2012
Oohashi, 2009

5mg/kg
7.35mg/kg

PO q 12-24h
PO q 24h

Starting doses of cyclosporine for various inflammatory diseases in cats described in the
literature. There is wide variation in dose and dose frequency utilized, corresponding with a lack
a consensus on the starting dose of cyclosporine for systemic immunosuppression in cats.
Additional research is needed in this area.
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Recommended Pre-treatment Examination
Due to cyclosporine’s unpredictable immunosuppressive properties, it is critical that
veterinarians rule out infectious disease prior to administration. It has been recommended that
veterinarians evaluate a through history and physical examination, in addition to performing
bloodwork (complete blood count, serum chemistry, urinalysis, feline leukemia virus and feline
immunodeficiency virus serology) prior to treatment41. Toxoplasmosis remains an important
concern in cats being treated with cyclosporine. Some authors report that being seronegative
increases the risk of developing clinical toxoplasmosis (if exposed) and therefore believe that
seronegative patients require more careful management50,85. In contrast, some authors report that
cyclosporine therapy re-activates latent infections and therefore believe that seropositive patients
are at a greater risk of clinical toxoplasmosis86
Drug Interactions
Cyclosporine has proven drug interactions with ketoconazole, itraconazole and
clarithromycin in cats51–53. However, multiple other drug interactions are possible due to drug
effects on the cytochrome P450 enzyme system. Drug interactions in other species have been
noted with the following frequently used drugs in cats: angiotensin-converting enzyme
inhibitors, allopurinol, aminoglycosides, cephalosporins, chloramphenicol, digoxin, diltiazem,
fluconazole, glucocorticoids, non-steroidal anti-inflammatory drugs, phenobarbitone, rifampin
and trimethoprim sulfa2. Additional studies are required to determine whether these drugs
represent clinically important drug interactions in feline patients.
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Complications of Cyclosporine Therapy
A clinical safety study for modified cyclosporine in cats documented multiple adverse
effects. In the study, cats were assessed via a six-week field study at 7mg/kg/day as a single daily
dose, followed by a twelve-week open label dose-tapering field study. The following adverse
effects were noted: vomiting (35.1%), weight loss (20.5%), diarrhea (15.1%), anorexia (14.1%),
lethargy (13.6%), hypersalivation (11.2%), behavioral disorders (8.8%), ocular discharge (6.8%),
sneezing (5.4%), gingival hyperplasia (4.4%) and polydipsia (2.9%). Other less common adverse
effects included bacterial dermatitis, hepatic lipidosis, small cell lymphoma, constipation,
toxoplasmosis, muscle wasting, ataxia, convulsions, polyuria, urinary tract infection,
inappropriate urination or defection, seborrhea, otitis externa, papilloma development,
leukotrichia, hypertrichosis, CBC abnormalities and increased creatinine, blood urea nitrogen
and alanine aminotransferase66. In other studies, gastrointestinal signs were the most prominent
adverse effects44,87–92. Additional studies have reported the following rare adverse effects: acute
bullous keratopathy and hemolytic uremic syndrome93,94.
Rarely, cyclosporine has been associated with the development of malignant neoplasia,
which may be associated with inhibition of cytotoxic T-cell mediated anti-tumor immune
surveillance95. In humans, cyclosporine is associated with a two-fold increase in the risk of
malignancy, with cyclosporine-treated organ transplant patients being at a twenty-eight fold
increased prevalence of lymphoma96. Lymphoma has also been reported in a case report of a dog
being treated with cyclosporine97. Multiple retrospective papers have investigated the incidence
of post-transplantation malignant neoplasia in cats treated with cyclosporine, with an incidence
rate of 9.5-24%98,99. The incidence rate of malignant neoplasia appears lower in patients treated
with cyclosporine for dermatological or immune-mediated disease conditions50.
12

Opportunistic infections, in particular toxoplasmosis, are another significant concern in
patients undergoing cyclosporine therapy. In 1999, the first potential link between cyclosporine
and development of toxoplasmosis was documented. In two of the three cases tachyzoites were
identified in the organs, but not in the allografts, suggestive of reactivation of a latent infection
following initiation of cyclosporine therapy100. However, a 2004 case report documented a newly
acquired fatal toxoplasmosis infection in a cat receiving cyclosporine at the licensed dose101.
This case report highlights the potential of excessive immunosuppression in individual patients
on doses of cyclosporine traditionally indicated for dermatological conditions. This prompts
further investigation into appropriate therapeutic drug monitoring techniques in cats. With regard
to toxoplasmosis, it is not always clear whether the patient had reactivation of a chronic infection
or developed a new infection with toxoplasmosis and, as such, serology for toxoplasmosis is
recommended prior to therapy100. Lappin et al., inoculated cats with Toxoplasma gondii to
evaluate the effect of cyclosporine on infection status. In this study, it was demonstrated that
administration of oral cyclosporine increased the severity of T. gondii infection in naïve animals,
but not in those previously exposed to T. gondii85. Cats on cyclosporine should be kept indoors
and should not be fed raw meat so as to minimize exposure to toxoplasmosis. Animals that are
seronegative prior to therapy may be at an increased risk of clinical toxoplasmosis50,85.
Cyclosporine has also been documented to reactivate feline herpesvirus-1 infection; however,
most clinical signs are mild and severe clinical manifestations are rare102.
Monitoring of Cyclosporine Therapy
Variability in individual response to cyclosporine has been documented in both dogs and
cats2,50. Potential explanations include differences in bioavailability, metabolism and T-cell
responses such as cytokine expression, lymphocyte proliferation, and/or apoptosis. Differences
13

in individual patient response can lead to excess immunosuppression and development of fatal
infections, or to an absence of immunosuppression and undertreatment. Therapeutic drug
monitoring is therefore recommended in patients receiving cyclosporine2,50. Therapeutic drug
monitoring has been extensively reviewed in dogs2; however, cyclosporine blood levels are the
only commercially available tool for therapeutic monitoring in cats. Additional research is
therefore needed to develop additional tools for therapeutic monitoring of cyclosporine in cats
Pharmacokinetic Monitoring in Cats
Trough Cyclosporine Concentrations
Recommendations for monitoring of cyclosporine therapy in cats include measurement of
trough cyclosporine levels in whole blood103. Whole blood is the sample of choice, as
cyclosporine concentrates in red blood cells2. A target twelve hour trough cyclosporine
concentration of 300-500ng/mL is recommended; however, trough levels are highly variable and
have a poor correlation with clinical efficacy9,42,103 This poor correlation has led to calls to reconsider therapeutic drug monitoring in cats42
Peak Cyclosporine Concentrations
Mehl et al., evaluated whole blood concentrations of cyclosporine following oral
administration in six healthy cats. In this study, cyclosporine concentrations two hours after
cyclosporine dosing correlated more closely with area-under-the-curve results than 12-hour post
administration concentrations. This suggests that peak whole blood cyclosporine levels may be a
better tool to evaluate cyclosporine therapy in cats42. However, therapeutic peak target
concentrations have not yet been established, thus limiting their clinical utility2,42.
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Area Under the Concentration-Time Curve (AUC) Monitoring
AUC monitoring is more highly correlated with clinical outcomes than trough
cyclosporine levels in humans104, and AUC was used as the gold standard in a recent feline study
comparing peak and trough cyclosporine levels42. Additional research is needed to determine if
AUC monitoring corresponds with clinical immunosuppression, and how it compares to peak
and trough cyclosporine monitoring. However, clinical application may be limited by the number
of blood samples required for AUC determination.
Pharmacodynamic Monitoring in Cats
Pharmacodynamic assays investigate cyclosporine’s effect on lymphocytes.
Pharmacodynamic monitoring of cyclosporine may include proliferation assays, assessment of
cytokine suppression or calcineurin inhibition assays. Pharmacodynamic monitoring is routinely
used in dogs; however, to date there are no studies on pharmacodynamic assays for cyclosporine
in cats. Proliferation assays have been utilized for many years and show a high correlation with
cyclosporine blood levels. Commonly utilized methodologies include measurement of the
proliferation responses of stimulated lymphocytes under the influence of cyclosporine.
Proliferation assays were first evaluated by Hibbins et al., who activated lymphocytes with
phytohaemagglutinin (PHA), and then incubated them with multiple drugs, including
cyclosporine. The gradient of inhibition then indicated the response to cyclosporine105. One of
the most commonly explored pharmacodynamic monitoring tools explored in dogs is inhibition
of lymphocyte cytokine suppression by cyclosporine. Cyclosporine is known to suppress
production of many NFAT regulated cytokines, including IL-2. Measuring T cell IL-2 and IFNγ suppression by cyclosporine using flow cytometric or PCR-based methods is commonly
utilized in dogs to determine the level of immunosuppression from cyclosporine2,106,107.
15

Calcineurin inhibition assays measure the direct effect of cyclosporine; however, they are rarely
performed due to their technically challenging nature. There are two different methodologies for
calcineurin inhibition assays. The first technique involves measurement of inhibition of target
enzyme activity, and the second involves measurement of immunological responses108.
Monitoring Conclusions
Therapeutic drug monitoring is indicated due to marked individual variations in response
to oral cyclosporine. Current therapeutic monitoring tools in cats are limited to pharmacokinetic
monitoring, and do not appear to correlate well with clinical efficacy. Therefore, additional
studies are required to allow for effective monitoring of cyclosporine therapy in cats.
Pharmacodynamic monitoring offers promise in this area

16

References
1.

Robson D. Review of the properties and mechanisms of action of cyclosporine with an
emphasis on dermatological therapy in dogs, cats and people. Vet Rec. 2003;152(25):768–
72.

2.

Archer TM, Boothe DM, Langston VC, et al. Oral cyclosporine treatment in dogs: a
review of the literature. J Vet Intern Med. 2014;28(1):1–20.

3.

Heusler K, Pletscher A. The controversial early history of cyclosporin. Swiss Med Wkly.
2001;131(21–22):299–302.

4.

Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new
antilymphocytic agent. Agents Actions. 1976;6(4):458–75.

5.

Calne RY, White DJG. Cyclosporin A - a powerful immunosuppressant in dogs with renal
allografts. Surg Transplant. 1977;5:595.

6.

Calne RY, White DJG, Rolles K, et al. Prolonged survival of pig orthotopic heart grafts
treated with cyclosporin A. Lancet. 1978;311(8075):1183–5.

7.

Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists.
Transplant Proc. 2004;36(2):S25–32.

8.

Fritsche L, Dragun D, Neumayer HH, et al. Impact of cyclosporine in the development of
immunosuppressive therapy. Transplant Proc. 2004;36(2):S80–2.

9.

Latimer KS, Rakich PM, Purswell BJ, et al. Effects of cyclosporin A administration in
cats. Vet Immunol Immunopathol. 1986;11(2):161–73.

10.

Abbas AK, Lichtman AH, Pober JS. Cellular and molecular immunology. 3rd Edition.
Philadelphia: W.B. Saunders; 1997:166.

11.

Viola JPB, Rao A. Role of the cyclosporin-sensitive transcription factor NFAT1 in the
allergic response. Mem Inst Oswaldo Cruz. 1997;92:147–55.

12.

Lan RY, Selmi C, Gershwin ME. The regulatory, inflammatory, and T cell programming
roles of interleukin-2 (IL-2). J Autoimmun. 2008;31(1):7–12.

13.

Cacalano NA, Chen BX, Cleveland WL, et al. Evidence for a functional receptor for
cyclosporin A on the surface of lymphocytes. Proc Natl Acad Sci. 2006;89(10):4353–7.

14.

Read RA. Cyclosporin and its treatment of ophthalmic diseases in animals. Aust Vet
Pract. 1996;26:86–91.

17

15.

Panyi G, Gáspár R, Krasznai Z, et al. Immunosuppressors inhibit voltage-gated potassium
channels in human peripheral blood lymphocytes. Biochem Biophys Res Commun.
1996;221(2):254–8.

16.

Attur MG, Patel R, Thakker G, et al. Differential anti-inflammatory effects of
immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide
synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res.
2000;49(1):20–6.

17.

Vaden SL. Cyclosporin and tacrolimus. Semin Vet Med Surg (Small Anim).
1997;12:161–6.

18.

Rafiq K, Charitidou L, Bullens DMA, et al. Regulation of the IL-10 production by human
T cells. Scand J Immunol. 2001;53(2):139–47.

19.

Gregory CR, Taylor NJ, Willits NH, et al. Response to isoantigens and mitogens in the
cat: effects of cyclosporin A. Am J Vet Res. 1987;48(1):126–30.

20.

Kyles AE, Gregory CR, Craigmill AL. Comparison of the in vitro antiproliferative effects
of five immunosuppressive drugs on lymphocytes in whole blood from cats. Am J Vet
Res. 2000;61(8):906–9.

21.

Prens EP, Joost T Van, Hegmans JP, t Hooft-Benne K, Ysselmuiden OE, Benner R.
Effects of cyclosporine receptors in psoriasis. J Am Acad Dermatol. 1995;33(6):947–53.

22.

Dupuy P, Bagot M, Micheal L, et al. Cyclosporin A inhibits the antigen-presenting
functions of freshly isolated human langerhans cells in vitro. J Invest Dermatol.
1991;96(4):408–13.

23.

Meng Q, Ying S, Corrigan CJ, et al. Effects of rapamycin, cyclosporin A, and
dexamethasone on interleukin 5- induced eosinophil degranulation and prolonged
survival. Allergy. 1997;52(11):1095–101.

24.

Marsella R, Olivry T. The ACVD task force on canine atopic dermatitis (XXII):
nonsteroidal anti-inflammatory pharmacotherapy. Vet Immunol Immunopathol.
2001;81:331–45.

25.

Scavuzzo M, Sagripanti A, Mosca F, et al. Modulation of β2 integrin phenotype, adhesion,
chemotaxis, and oxidative burst of neutrophils by cyclosporine. Biomed Pharmacother.
2001;55:61–9.

26.

Iverson L, Svendsen M, Kragballe K. Cyclosporin A down-regulates the LTA4 hydrolase
level in human keratinocyte cultures. Acta Derm Venereol. 1996;76:424–8.

27.

Cockerill GW, Bert AG, Ryan GR, et al. Regulation of granulocyte-macrophage colonystimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the
T-cell transcription factor NFAT. Blood. 1995;86(7):2689–98.
18

28.

Cirillo R, Triggiani M, Siri L, et al. Cyclosporin A rapidly inhibits mediator release from
human basophils presumably by interacting with cyclophilin . J Immunol.
1990;144(10):3891–7.

29.

Wong RL, Winslow CM, Kevin DC. The mechanisms of action of cyclosporin A in the
treatment of psoriasis. Immunol Today. 1993;14(2):69–74.

30.

Marone G, Triggiani M, Cirillo R, et al. Cyclosporin A inhibits the release of histamine
and peptide leukotrine C4 from human lung mast cells. Ric Clin Lab. 1988;18(1):53–9.

31.

Hatfield SM, Roehm NW. Cyclosporine and FK506 inhibition of murine mast cell
cytokine production. J Pharmacolgy Exp Ther. 1992;260(2):680–8.

32.

Garcia G, Ferrer L, Demora F, et al. Inhibition of histamine release from dispersed canine
skin mast cells by cyclosporin A, rolipram and salbutamol, but not by dexamethasone or
sodium cromoglycate. Vet Dermatol. 1998;9(2):81–6.

33.

Ezeamuzie IC, Assem ES. Inhibition of histamine release from human lung and rat
peritoneal mast cells by cylosporin-A. Agents Actions. 1990;30(1–2):110–3.

34.

Stellato C, de Paulis A, Ciccarelli A, et al. Anti-inflammatory effect of cylosporin A on
human skin mast cells. J Invest Dermatol. 1992;98(5):800–4.

35.

Misra UK, Gawdi G, Pizzo SV. Cyclosporin A inhibits inositol 1,4,5-trisphosphate
binding to its receptors and release of calcium from intracellular stores in peritoneal
macrophages. J Immunol. 1998;161:6122–7.

36.

Karashima T, Hachisuka H, Sasai Y. FK506 and cyclosporin A inhibit growth factorstimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the
cell cycle. J Dermatol Sci. 1996;12(3):246–54.

37.

Andrew SE. Immune-mediated canine and feline keratitis. Vet Clin North Am - Small
Anim Pract. 2008;38(2):269–90.

38.

Spiess AK, Sapienza JS, Mayordomo A. Treatment of proliferative feline eosinophilic
keratitis with topical 1.5% cyclosporine: 35 cases. Vet Ophthalmol. 2009;12(2):132–7.

39.

Dean E, Meunier V. Feline eosinophilic keratoconjunctivitis: A retrospective study of 45
cases (56 eyes). J Feline Med Surg. 2013;15(8):661–6.

40.

Mealey KL, Fidel J. P-glycoprotein mediated drug interactions in animals and humans
with cancer. J Vet Intern Med. 2015;29(1):1–6.

41.

Whitehouse W, Viviano K. Update in feline therapeutics: clinical use of 10 emerging
therapies. J Feline Med Surg. 2015;17(3):220–34.

19

42.

Mehl ML, Kyles AE, Craigmill AL, et al. Disposition of cyclosporine after intravenous
and multi-dose oral administration in cats. J Vet Pharmacol Ther. 2003;26:349–54.

43.

Brooks W. Cyclosporine [Internet]. Veterinary Partner. 2017. Available from:
https://veterinarypartner.vin.com/default.aspx?pid=19239&id=4952029

44.

Steffan J, Strehlau G, Maurer M, et al. Cyclosporin A pharmacokinetics and efficacy in
the treatment of atopic dermatitis in dogs. J Vet Pharmacol Ther. 2004;27(4):231–8.

45.

Miller R, Schick AE, Boothe DM, et al. Absorption of transdermal and oral cyclosporine
in six healthy cats. J Am Anim Hosp Assoc. 2013;50(1):36–41.

46.

Koch SN, Torres SMF, Diaz S, et al. Subcutaneous administration of ciclosporin in 11
allergic cats – a pilot open-label uncontrolled clinical trial. Vet Dermatol. 2018;29(2):e43107.

47.

Gregory CR, Hietala SK, Pedersen NC, et al. Cyclosporine pharmacokinetics in cats
following topical ocular administration. Transplantation. 1989;47(3):516–9.

48.

Freeman DJ. Pharmacology and pharmacokinetics of cyclosporine. Clin Biochem.
1991;24:9–14.

49.

Fisher GJ, Duell EA, Nickoloff BJ, et al. Levels of cyclosporin in epidermis of treated
psoriasis patients differentially inhibit growth of keratinocytes cultured in serum free
versus serum containing media. J Invest Dermatol. 1988;91(2):142–6.

50.

Colombo S, Sartori R. Ciclosporin and the cat: current understanding and review of
clinical use. J Feline Med Surg. 2018;20(3):244–55.

51.

McAnulty JF, Lensmeyer GL. The effects of ketoconazole on the pharmacokinetics of
cyclosporine A in cats. Vet Surg. 1999;28:448–55.

52.

Katayama M, Katayama R, Kamishina H. Effects of multiple oral dosing of itraconazole
on the pharmacokinetics of cyclosporine in cats. J Feline Med Surg. 2010;12(6):512–4.

53.

Katayama M, Nishijima N, Okamura Y, et al. Interaction of clarithromycin with
cyclosporine in cats: pharmacokinetic study and case report. J Feline Med Surg.
2012;14(4):257–61.

54.

Maurer G, Loosli HR, Schreier E, et al. Disposition of cyclosporine in several animal
species and man. I. Structural elucidation of its metabolites. Drug Metab Dispos.
1984;12(1):120–6.

55.

Venkaramanan R, Wang CP, Habucky K, et al. Species-specific cyclosporine metabolism.
Transplant Proc. 1988;20(2):680–3.

20

56.

Rosano TG, Freed BM, Cerilli J, et al. Immunosuppressive metabolites of cyclosporine in
the blood of renal allograft recipients. Transplantation. 1986;42(3):262–7.

57.

Shah SS, Sanda S, Regmi NL, et al. Characterization of cytochrome P450-mediated drug
metabolism in cats. J Vet Pharmacol Ther. 2007;30(5):422–8.

58.

Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors. Evaluation of specificities
in the vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab
Dispos. 1995;23:154–8.

59.

Dahlinger J, Gregory C, Bea J. Effect of ketoconazole on cyclosporine dose in healthy
dogs. Vet Surg. 1998;27(1):64–8.

60.

Butman SM, Wild JC, Nolan PE, et al. Prospective study of the safety and financial
benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J
Hear Lung Transpl. 1991;10(3):351–8.

61.

D’mello A, Venkaramanan R, Satake M, et al. Pharmacokinetics of the cyclosporine
ketoconazole interaction in dogs. Res Commun Chem Pathol Pharmacol. 1989;64(3):441–
54.

62.

First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by
ketoconazole administration in renal transplant recipients. Transplantation.
1991;51(2):365–70.

63.

First MR, Schroeder TJ, Michael A, et al. Cyclosporine-ketoconazole interaction. Longterm follow-up and preliminary results of a randomized trial. Transplantation.
1993;55(5):1000–4.

64.

Shah SS, Sasaki K, Hayashi Y, et al. Inhibitory effects of ketoconazole, cimetidine and
erythromycin on hepatic CYP3A activities in cats. J Vet Med Sci. 2009;71(9):1151–9.

65.

Kovalik M, Thoday KL, van den Broek AH. The use of ciclosporin A in veterinary
dermatology. Vet J. 2012;193:317–25.

66.

Atopica for Cats [Product Insert]. Elanco US Inc.; 2016.

67.

Irwin KE, Beale KM, Fadok VA. Use of modified ciclosporin in the management of feline
pemphigus foliaceus: a retrospective analysis. Vet Dermatol. 2012;23(5).

68.

Guaguere E, Fontaine J. P-69 efficacy of cyclosporin in the treatment of feline urticaria
pigmentosa: two cases. Vet Dermatol. 2004;15(S1):63.

69.

Fontaine J, Heilmann M. P-70 Idiopathic facial dermatitis of the Persian cat: three cases
controlled with cyclosporine. Vet Dermatol. 2004;15(s1):64.

21

70.

Olivry T, Power HT, Woo JC, Moore PF, Tobin DJ. Anti-isthmus autoimmunity in a
novel feline acquired alopecia resembling pseudopelade of humans. Vet Dermatol.
2000;11(4):261–70.

71.

Lobetti R. Lymphocytic mural folliculitis and pancreatic carcinoma in a cat. J Feline Med
Surg. 2015;17(6):548–50.

72.

Noli C. Extra-label use of cyclosporine. In: Proceedings of the 6th World Congress of
Veterinary Dermatology. Hong Kong, China; 2008. p. 251–6.

73.

Gregory CR, Gourley IM, Taylor NJ, et al. Preliminary results of clinical renal allograft
transplantation in the dog and cat. J Vet Intern Med. 1987;1(2):53–60.

74.

Gregory CR, Gourley IM, Broaddus TW, et al. Long term survival of a cat receiving a
renal allograft from an unrelated donor. J Vet Intern Med. 1990;4:1–3.

75.

Schmiedt CW, Holzman G, Schwarz T, et al. Survival, complications, and analysis of risk
factors after renal transplantation in cats. Vet Surg. 2008;37(7):683–95.

76.

Padrid PA, Cozzi P, Leff AF. Cyclosporine A inhibits airway reactivity and remodelline
after chronic antigen challenge in cats. Am J Respir Crit Care Med. 1996;154(6):1812–8.

77.

Nafe LA, Leach SB. Treatment of feline asthma with ciclosporin in a cat with diabetes
mellitus and congestive heart failure. J Feline Med Surg. 2015;17(12):1073–6.

78.

Stokol T, Blue JT. Pure red cell aplasia in cats: 9 cases (1989-1997). J Am Vet Med
Assoc. 1999;214(1):75–9.

79.

Viviano KR, Webb JL. Clinical use of cyclosporine as an adjunctive therapy in the
management of feline idiopathic pure red cell aplasia. J Feline Med Surg.
2011;13(12):885–95.

80.

Mischke R. Cyclosporin A therapy in a cat with pure red cell aplasia. Bern Munch
Tierarztl Wochenschr. 1998;111(11–12):432–7.

81.

Garon CL, Scott MA, Selting KA, et al. Idiopathic thrombocytenic purpura in a cat. J Am
Anim Hosp Assoc. 1999;35:464–70.

82.

Jergens AE. Feline idiopathic inflammatory bowel disease. J Feline Med Surg.
2012;14(7):445–58.

83.

Jergens AE. Which drugs are used to manage feline inflammatory bowel disease? Clin Br.
2015;Sept:26–36.

84.

Oohashi E, Yamada K, Oohashi M, et al. Chronic progressive polyarthritis in a female cat.
J. Vet. Med. Sci. 2010; 72(4):511-514.
22

85.

Lappin MR, Vanlare KA, Seewald W, et al. Effect of oral administration of cyclosporine
on toxoplasma gondii infection status of cats. Am J Vet Res. 2015;76(4):351–7.

86.

Aronson LR. Update on the current status of kidney transplantation for chronic kidney
Disease in Animals. Vet Clin North Am - Small Anim Pract. 2016;46(6):1193–218.

87.

Noli C, Scarampella F. Prospective open pilot study on the use of ciclosporin for feline
allergic skin disease. J Small Anim Pract. 2006;47(8):434–8.

88.

Vercelli A, Raviri G, Cornegliani L. The use of oral cyclosporin to treat feline dermatoses:
A retrospective analysis of 23 cases. Vet Dermatol. 2006;17(3):201–6.

89.

Wisselink MA, Willemse T. The efficacy of cyclosporine A in cats with presumed atopic
dermatitis: a double blind, randomised prednisolone-controlled study. Vet J.
2009;180(1):55–9.

90.

Heinrich NA, McKeever PJ, Eisenschenk MC. Adverse events in 50 cats with allergic
dermatitis receiving ciclosporin. Vet Dermatol. 2011;22(6):511–20.

91.

King S, Favrot C, Steffan J, et al. A randomized double-blinded placebo-controlled study
to evaluate an effective ciclosporin dose for the treatment of feline hypersensitivity
dermatitis. Vet Dermatol. 2012;23(5).

92.

Roberts ES, Vanlare KA, Strehlau G, et al. Safety, tolerability, and pharmacokinetics of 6month daily dosing of an oral formulation of cyclosporine (ATOPICA for cats ® ) in cats.
J Vet Pharmacol Ther. 2013;37:161–8.

93.

Pierce KE, Wilkie DA, Gemensky-Metzler AJ, et al. An association between systemic
cyclosporine administration and development of acute bullous keratopathy in cats. Vet
Ophthalmol. 2016;19:77–85.

94.

Aronson LR, Gregory C. Possible hemolytic uremic syndrome in three cats after renal
transplant and cyclosporine therapy. Vet Surg. 1999;28:135–40.

95.

Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treatment: long-term
safety of ciclosporin in canine atopic dermatitis. Vet Rec. 2014;174(2):3–12.

96.

Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J
Autoimmun. 1989;2(5):723–31.

97.

Blackwood L, German AJ, Stell AJ, et al. Multicentric lymphoma in a dog after
cyclosporine therapy. J Small Anim Pract. 2004;45(5):259–62.

98.

Wooldridge JD, Gregory CR, Mathews KG, et al. The prevalence of malignant neoplasia
in feline renal-transplant recipients. Vet Surg. 2002;31(1):94–7.

23

99.

Schmiedt CW, Grimes JA, Holzman JF, et al. Incidence and risk factors for development
of malignant neoplasia after feline renal transplantation and cyclosporine-based
immunosuppression. Vet Comp Oncol. 2009;7(1):45–53.

100. Bernsteen L, Gregory CR, Aronson LR, et al. Acute toxoplasmosis after renal transplants
in three cats and a dog. J Am Vet Med Assoc. 1999;215:1123–6.
101. Last RD, Suzuki Y, Manning T, et al. A case of fatal systemic toxoplasmosis in a cat
being treated with cyclosporin A for feline atopy. Vet Dermatol. 2004;15(3):194–8.
102. Lappin MR, Roycroft LM. Effect of ciclosporin and methylprednisolone acetate on cats
previously infected with feline herpesvirus 1. J Feline Med Surg. 2015;17(4):353–8.
103. Bernsteen L, Gregory CR, Kyles AE, et al. Renal transplantation in cats. Clin Tech Small
Anim Pract. 2000;15(1):40–5.
104. Kasiske BL, Heim-Duthoy K, Rao KV, et al. The relationship between cyclosporine
pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients.
Transplantation. 1988;36(5):716–22.
105. Hibbins M, Allen RD, Chapman JR. Inhibition of PHA lymphocyte responses by
cyclosporine and methylprednisolone. Transplant Proc. 1990;22(5):2137–8.
106. Archer TM, Fellman CL, Stokes JV, et al. Pharmacodynamic monitoring of canine T-cell
cytokine responses to oral cyclosporine. J Vet Intern Med. 2011;25:1391–7.
107. Fellman CL, Archer TM, Stokes JV, et al. Effects of oral cyclosporine on canine T-cell
expression of IL-2 and IFN-gamma across a 12-h dosing interval. J Vet Pharmacol Ther.
2016;39(3):237–44.
108. van Rossum HH, de Fijter JW, van Pelt J. Pharmacodynamic monitoring of calcineurin
inhibition therapy: principles, performance and perspectives. Ther Drug Monit.
2010;32(1):3–10.

24

CHAPTER II
EFFECTS OF CYCLOSPORINE ON FELINE LYMPHOCYTES ACTIVATED IN VITRO1
Introduction
Cyclosporine A (CsA) is a calcineurin inhibitor licensed for the management of atopic
dermatitis in cats. Due to its inhibition of T-lymphocyte function1–3 and favorable toxicity
profile, cyclosporine is also being used with increasing frequency in cats to prevent renal
transplant rejection4,5, and in the management of inflammatory and immune-mediated diseases
such as inflammatory bowel disease6, immune-mediated hemolytic anemia7,8, immune-mediated
thrombocytopenia9,10, chronic progressive polyarthritis11,12 and pure red cell aplasia13, amongst
others.
Variability in individual responses to cyclosporine has been documented in both dogs3
and cats14. Factors that help explain dissimilarity in patient responses include differences in
bioavailability, metabolism, and T cell responses such as cytokine expression, lymphocyte
proliferation and/or apoptosis.
Previous research has shown that cyclosporine decreases the expression of nuclear factor
of activated T cell (NFAT)-regulated cytokines including IL-2, IFN- and TNF-α in people15, IL2 and IFN- in dogs16, and IL-2, IL-4, IFN- and TNF-α in cats1. Decreased expression of these
cytokines results in decreased T-cell function and proliferation, thereby leading to

This chapter is published as an article in Veterinary Immunology and Immunopathology. Cridge H, Kordon A,
Pinchuk LM et al. Effects of cyclosporine on feline lymphocytes activated in vitro. Vet Immunol. Immunopathol.,
2020;219:109962
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immunosuppression. Although the effects of CsA on cytokine expression have been evaluated1,
the direct effects of CsA on lymphocyte proliferation have not been evaluated in cats. Human
literature documents that cyclosporine also induces apoptosis of lymphoid cells, which is
suspected to contribute in part to its immunosuppressive properties17. The effects of CsA on
lymphocyte apoptosis have also not yet been evaluated in cats. Thus, further studies are
warranted to investigate the effects of CsA on feline lymphocyte proliferation and apoptosis
Cyclosporine-mediated immunosuppression can have significant unintended clinical
consequences, including the development of secondary infections such as toxoplasmosis and
feline herpesvirus-114. A case report published in 2004 documented that a cat receiving the
licensed dose of cyclosporine developed a fatal toxoplasmosis infection18. The authors suspected
that the cat had a marked reduction in T-lymphocyte function induced by cyclosporine, although
it was unclear why this individual cat had such significant immunosuppression relative to other
cats receiving the same drug dosage. Case reports such as this prompt further investigation into
the immunosuppressive mechanism of cyclosporine in cats, and into individual responses to the
drug. Given concerns regarding the potential for the development of clinical toxoplasmosis in
cats treated with cyclosporine, Lappin et al. investigated the effects of cyclosporine on both
naïve and Toxoplasma seropositive individuals that were subsequently infected with T. gondii. In
the study, it was noted that cyclosporine therapy worsened the severity of infection in naïve cats,
but not in those cats that had been previously exposed to T. gondii. This experimental study
suggests that naïve cats may be at greater risk of clinical toxoplasmosis during cyclosporine
therapy19. In contrast, extensive clinical experience with feline renal transplantation patients
receiving cyclosporine as part of their associated immunosuppressive therapy suggests that pre-
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treatment positive Toxoplasma serology actually increases the risk of subsequent clinical
toxoplasmosis, consistent with drug-associated recrudescent of occult disease20
Therapeutic drug monitoring (TDM) is recommended in patients receiving
cyclosporine3,14, with two methods commonly utilized. One common method is pharmacokinetic
monitoring, via measurement of peak and/or trough cyclosporine blood concentrations.
However, there are no clear guidelines on therapeutic targets3, and cyclosporine blood
concentrations do not appear to correlate with clinical efficacy in cats4. It has therefore been
suggested that TDM strategies for cyclosporine in cats should be re-evaluated21.
Pharmacodynamic monitoring is available in humans and dogs for TDM of cyclosporine, and is
considered to supplement information provided by assessment of cyclosporine blood
concentrations3. Pharmacodynamic assays for TDM of cyclosporine have not yet been
established in cats.
The purposes of this study were, firstly, to design and optimize a suitable activation
protocol for T cells in cats for subsequent pharmacodynamic assessment of cyclosporine and,
secondly to determine whether effects on lymphocyte proliferation and/or apoptosis contribute to
the immunosuppressive action of cyclosporine in cats.
Materials and Methods
Experimental Animals
This project involved 6 healthy client-owned domestic shorthair cats. Six to eight animals
have been suggested as sufficient population size to evaluate the pharmacokinetics of a drug22.
Two cats were male neutered, and 4 cats were female spayed. The average age at the time of
enrollment was 8 years and 4 months. Prior to inclusion in the study, each cat received a physical
examination, and a complete blood count and serum biochemistry profile were evaluated, with
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no significant abnormalities noted. The cats were not on any medications at the time of inclusion
in the study. Informed owner consent was obtained before sample collection, and restraint and
blood collection protocols were approved by the Mississippi State University Institutional
Animal Care and Use Committee (IACUC).
Blood Sampling and Peripheral Blood Mononuclear Cell (PBMC) Isolation
Heparinized peripheral blood was obtained via jugular puncture. Initially, 5 mL of whole
blood from each cat was added to 45mL of phosphate buffered saline (PBS). The sample was
then centrifuged at 500 g for 7-10 minutes to wash the cells. Next, cell suspensions were layered
on Histopaque-1077 (Sigma Aldrich, St Louis, MO, USA), and centrifuged at 500 g for 30
minutes to obtain enriched peripheral blood mononuclear cells (PBMCs). Following
centrifugation, PBMCs were collected from the interface and were washed three times with PBS
at 500 g for 7-10 minutes. Residual erythrocytes were removed from the PBMCs with lysis
buffer (BD Biosciences, San Jose, CA, USA) for 5 minutes with gentle agitation. Then, PBMCs
were counted and assessed for viability by using a hemocytometer and trypan blue exclusion
dye. The cells were then used immediately for in vitro stimulation studies.
Lymphocyte Stimulation Protocols and Cell Proliferation Assessment
Enriched PBMCs were cultured in vitro in medium [RPMI-1640 medium (Sigma
Aldrich, St Louis, MO), supplemented with 10% heat-inactivated fetal bovine serum (Sigma
Aldrich, St Louis, MO), 100U/mL of penicillin and streptomycin (Sigma Aldrich, St Louis,
MO), and 0.25g/mL amphotericin B (Sigma Aldrich, St. Louis, MO)]. Preliminary experiments
revealed that ionomycin (0.6-1.0 µM) and phorbol myristate acetate (10.0-15.0 µg/mL) at
varying concentrations failed to result in stimulation of feline lymphocytes (data not shown).
28

Therefore, 5g/mL concanavalin A (ConA) at 5 CO2 % was selected for the stimulation of
lymphocytes based on previous studies 1. Cell suspensions were transferred to 96-well plates
(Evergreen Scientific, Rancho Dominguez, CA), and stimulator and inhibitors were added to cell
suspensions.
Four groups of cell culture were analyzed as follows:
i)

Cells only (negative control)

ii)

Cells + 5g/mL ConA

iii)

Cells + 500 ng/mL CsA

iv)

Cells + 5g/mL ConA + 500 ng/mL CsA

All treatments were incubated at 37.0°C and 5% CO2. Cell suspension viable cell counts were
analyzed daily for 6 days using 0.4% trypan blue exclusion dye (Sigma Aldrich, St. Louis, MO)
and a Neubauer hemocytometer chamber (Webber Scientific, Hamilton, NJ). Cells that did not
have intracellular staining with trypan blue stain were recorded as “alive”, and cells that had
intracellular staining were recorded as “necrotic”.
Apoptosis Assay
An apoptosis assay was applied as described previously, with minor modifications23, to
PBMCs from a randomly selected cat. Cell suspensions were harvested and washed in PBS by
centrifugation at 500 g for 7 minutes. Apoptosis was assessed by using an Annexin V-FITC
Apoptosis Kit according to manufacturer’s instructions (BioVision, Inc., Mountain View, CA).
Briefly, after washing, the cells were resuspended in 1x Binding Buffer and incubated with
Annexin V-FITC and propidium iodide for 5 minutes at room temperatures in the dark to detect
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early and late apoptotic changes. The samples were then analyzed by NovoCyte Flow Cytometry
using two-color analyses with Dot Plot Quadrant Statistics.
Enriched PBMCs were cultured in vitro, in the same manner as for the lymphocyte proliferation
study noted above. Four groups of cell culture were then analyzed as follows:
i) Cells only (negative control)
ii) Cells + 5g/mL ConA
iii) Cells + 500 ng/mL CsA
iv) Cells + 5g/mL ConA + 500 ng/mL CsA
The apoptosis assay was performed on day 1 and day 5. Each treatment was performed and
analyzed in triplicate, with the exception of the negative control group which was not repeated.
Statistical Analysis
Live cell counts were log10 transformed prior to analysis. A linear mixed model using
PROC MIXED in SAS for Windows 9.4 (SAS Institute, Inc., Cary, NC) was fit for live cells, in
a model that included day, treatment and their interaction as fixed effects. Cat identity was
included as a random effect with variance components covariance structure. In the case of the
significant interaction term, differences in least squares means between each pair of days for
each treatment group were calculated and between ConA and ConA-activated PBMCs in the
presence of CsA treatment groups for each day using an LSMESTIMATE statement.
Linear models with PROC MIXED in SAS for Windows 9.4 were used for percentage of
live cells, early apoptotic cells, late apoptotic cells, and necrotic cells. Initial models for late
apoptosis and necrosis did not meet the assumptions of normality and homoscedastiticity;
therefore, the data for these outcomes was log10 transformed. Fixed effects for each outcome
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(live cells, early apoptotic cells, log10 late apoptotic cells, and log10 necrotic cells) were
treatment, day and their interaction. In the case of a significant interaction term, differences in
least squares means between day 1 and day 5 for each of the treatments and between treatments
for each day were calculated using an LSMESTIMATE statement.
The simulate adjustment for multiple comparisons was used in the case of the significant
terms. The distribution of the conditional residuals for each model was evaluated to ensure the
assumptions of normality and homoscedasticity for the statistical method had been met.
Statistical analysis was not performed on the negative control group as repeat analysis was not
performed in the negative control group. An alpha level of 0.05 was used to determine statistical
significance.
Results
Analysis of Cyclosporine Effects on Feline Lymphocytes In Vitro
Both phorbol myristate acetate (PMA) and ionomycin were initially explored as agonists
but failed to result in lymphocyte proliferation (data not shown). Five µg/mL ConA was
therefore used for cell stimulation, as previously documented by Kuga et al., 2008. In the present
study, there was a significant interaction between day and treatment (P < 0.001). ConA
incubation with PBMCs resulted in a statistically significant increase in live cell counts at days 2,
3, 4, 5 and 6 compared to day 1 (P < 0.001). Maximal stimulatory effects of ConA occurred on
day 5, as day 5 had significantly greater live cell counts than day 6 (P = 0.0151) (Error!
Reference source not found.). Addition of cyclosporine to ConA-activated feline PBMCs
resulted in a statistically significant decrease in live cell counts relative to when cells were
exposed to ConA alone (Error! Reference source not found.). The decrease was significant at
days 3, 4, 5 and 6 (P < 0.001), but a significant difference was not detected on day 1 (P = 0.999)
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or day 2 (P = 0.960). Minimal variability in individual cat responses to CsA was observed, as
indicated by small standard error from the mean data.
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Figure 2.1

Cyclosporine inhibits lymphocyte proliferation in response to ConA

Exposure to 5µg/mL ConA results in proliferation of feline lymphocytes, with a peak of
maximum proliferation on day 5 (A). Addition of 500ng/mL CsA results in a statistically
significant suppression of lymphocyte proliferation on days 3, 4, 5 and 6 (B). Statistical analysis
was performed on log10 transformed cell counts. Statistically significant differences in
lymphocyte count relative to day 1 are indicated by *. The error bars indicate the standard error
from the mean in lymphocyte counts amongst the 6 cats evaluated.
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Assessment of Cyclosporine Effects on Early and Late Apoptotic Changes in Feline PBMCs
Assessment of apoptosis in feline PBMCs via flow cytometry documented both early and
late apoptotic changes in the cells exposed to cyclosporine (Error! Reference source not
found.). There was a significant interaction between day and treatment for the percentage of live
cells outcome (P < 0.001). Significant decreases in the percentage of live cells were evident at
day 5 in PBMCs exposed to CsA alone (P < 0.001), ConA alone (P = 0.002), and ConAactivated PBMCs in the presence of CsA (P < 0.001) (Error! Reference source not found.).
There was a significant interaction between day and treatment for the early apoptosis outcome (P
< 0.001). There was a significant decrease in the percentage of early apoptotic cells in the
PBMCs exposed to ConA (P < 0.001) (Error! Reference source not found.). Significant
increases were evident in the percentage of early apoptotic cells exposed to CsA (P < 0.001). No
significant change was identified with ConA-activated PBMCs in the presence of CsA (P =
0.135) for early apoptotic cells (Error! Reference source not found.). There was a significant
interaction between day and treatment for the log10 late apoptosis outcome (P < 0.001).
Significant increases in the percentage of log10 late apoptotic cells were shown in all
experimental groups (P < 0.001), with the most dramatic increases in PBMCs treated with both
ConA and CsA (Error! Reference source not found.). Finally, there was a significant
interaction between day and treatment for the log10 necrosis outcome (P = 0.027). Significant
increases in the percentage of necrotic cells were documented at day 5 in PBMCs exposed to
ConA, CsA and both reagents (P < 0.001) (Error! Reference source not found.).
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Figure 2.2

Apoptotic changes in feline PBMCs exposed to cyclosporine by flow cytometry

Apoptosis assay results on day 1 (A) and day 5 (B) in response to incubation with 5µg/mL
ConA, 500ng/mL CsA, and 5µg/mL ConA + 500ng/mL CsA respectively. Results are displayed
as a percentage of total cell count. Cells without an activator or inhibitor was used as a negative
control. Q1 – necrosis, Q2 – late apoptosis, Q3 – early apoptosis, Q4 – live cells.
.
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Figure 2.3

Figure A.1
Statistical interpretation of early and late apoptotic changes in
feline PBMCs

Statistical interpretation of apoptosis assay in response to incubation with 5µg/mL ConA,
500ng/mL CsA, and 5µg/mL ConA + 500ng/mL CsA respectively. Statistical analysis was not
performed on the negative control group as repeat analysis was not performed in the negative
control group. Results are displayed as a percentage of total cell count. Three biological
replicates were performed. Statistically significant differences between day 1 and day 5 are
indicated by *.

36

Discussion
The results of our present study demonstrated that 5 µg/mL ConA effectively induced
lymphocyte proliferation, with the maximal proliferation occurring on day 5 of incubation (5%
CO2 and 37°C). A ConA concentration of 5 µg/mL was selected based on previous literature1.
Our activation protocol differs from a previous study that utilized a similar concentration of
ConA (5 µg/mL) under different conditions (24 hours of incubation in 37°C in humidified air
with 5% CO2)1. Unlike our study, the previous study did not assess a temporal relationship
between duration of exposure to activators and cell counts. Although PMA and ionomycin were
initially studied as activators, based on reported effectiveness in previous canine studies16,24,25,
they failed to provide sufficient activation of lymphocytes. PMA, ionomycin and ConA were
originally selected for evaluation as they are T-cell agonists. PMA activates the signal
transduction enzyme protein kinase C, whilst ionomycin increases the intracellular level
ofcalcium, thus stimulating T cells26,27. Concanavalin A, in contrast, binds and cross-links
components of the T-cell receptor28. The differences in mechanisms of action of PMA,
ionomycin and ConA may help explain the differences in species response to these T-cell
activators. Interestingly, the previous study that documented T-cell activation in cats also used
ConA1. Additional studies are required to determine if feline T lymphocytes are resistant to
activation by PMA/ionomycin, or if further dose optimization of these two activators is required.
The activation protocol developed in our study may provide a basis for future studies
pharmacodynamically investigating the effects of immunosuppressive therapy on ConAactivated lymphocytes in cats.
Addition of cyclosporine to ConA-stimulated cells resulted in decreased live cell counts
relative to those cells exposed to ConA alone. The dose of CsA was selected based on previous
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unpublished work by our research group. Previous studies have documented that CsA has no
apparent cytotoxicity on feline lymphocytes, at drug concentrations from 10-1000 ng/mL, in the
presence of ConA at 5µg/mL1. Our study confirms that, as in other species, CsA inhibits
lymphocyte stimulation, as documented by live cell counts, in cats.
Immunosuppressive agents, including glucocorticoids and cyclosporine, have been shown
to induce apoptosis in human cell lines17. Apoptosis is defined as biologically programmed cell
death, characterized by nuclear DNA degradation, nuclear degeneration and condensation.
Necrosis, in contrast, is defined as death of tissue caused by chemical or physical injury29. Our
study confirms that CsA also induces both early and late apoptotic change in feline PBMCs as
documented by flow cytometry. Furthermore, our data showed significant pro-apoptotic effects
of CsA on resting and activated feline PBMCs. The apoptosis assay revealed a statistically
significant increase in the percentage of cells undergoing early apoptosis when exposed to CsA.
In addition, CsA induced late apoptosis. Cells exposed to both ConA and CsA had more
dramatic late apoptotic effects than the group exposed to CsA alone. One potential explanation
for this phenomenon is that cyclosporine acts in the G0 phase of the cell cycle30. The increase in
cell proliferation associated with ConA may increase the number of times a cell is in Go and thus
susceptible to cyclosporine. Horigome et. al. previously suggested that immunosuppression may
be influenced by lymphocyte susceptibility to apoptosis, thus making apoptosis an interesting
area of research when investigating cyclosporine-induced immunosuppression. Differences in
susceptibility to apoptosis may play a key role in individual feline responses to cyclosporine.
Further investigation is needed to determine the significance of individual variation in apoptosis
induced by cyclosporine in cats, and whether this variability influences clinical response to
immunosuppressive therapy.
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Pharmacodynamic monitoring of cyclosporine has been recommended in dogs due to
marked differences in dog-to-dog responses to oral cyclosporine3. Cyclosporine is a calcineurin
inhibitor that inhibits production of NFAT-regulated cytokines, including IL-215,16,24. IL-2 is
essential for T-cell proliferation, and as such T-lymphocyte proliferation can be used as a
surrogate marker of drug action. In fact, cell proliferation has been used as a marker of
cyclosporine action in a number of other studies16,24,25. Our study demonstrated that cell
proliferation appears to be viable as an indicator of cyclosporine action in cats. Although our
study determined a viable protocol for ConA-induced proliferation of lymphocytes that was
sensitive to the effects of cyclosporine, future studies would be needed to optimize the current
activation protocol for use on whole blood or for use with different research technologies such as
flow cytometric or RT-qPCR measurement of cytokine expression, to allow for the subsequent
development of a more commercially feasible pharmacodynamic monitoring tool for
cyclosporine in cats.
In conclusion, our study designed and optimized an activation protocol for feline
lymphocytes with concanavalin A (5 µg/mL in 5% CO2 at 37°C for 5 days) and documented that
exposure to cyclosporine resulted in inhibition of cell proliferation, as noted by live cell counts.
In addition, our study documented that cyclosporine induced apoptosis of lymphocytes in cats.
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CHAPTER III
ADDITIONAL EXPERIMENTS
1. Investigation into the use of Phorbol Myristate Acetate and Ionomycin as T-cell mitogens
in Cats
Introduction
Pharmacodynamic assays evaluate the effect of a drug on a target cell or tissue and, in the
case of cyclosporine, the target cell is the T lymphocyte. Many pharmacodynamic biomarkers of
cyclosporine action have been investigated in humans and dogs, including lymphocyte
proliferation, surface antigen expression, calcineurin activity and cytokine production1,2,11,3–10.
Pharmacodynamic studies investigating cyclosporine in cats are limited. In 1987, Gregory et al.
documented a non-cytotoxic decrease in lymphocyte response when cyclosporine was added to a
whole-blood lymphocyte stimulation assay, thus indicating that cyclosporine has antilymphocytic properties in cats, as in other species12. Further work published in 2000 documented
cyclosporine’s anti-proliferative effects on feline lymphocytes via the use of various T-cell and
mixed T-cell and B-cell mitogens, including concanavalin A (ConA) and pokeweed (PMW)13.
Mitogens are required to induce maximal lymphocyte proliferation prior to assessing the effect
of cyclosporine on T cells. However, little further research has been published on T-cell
mitogens in cats. Preliminary studies performed by Kyles et al. indicated that Con A and PMW
produced the greatest and most consistent degree of T cell proliferation in cats; however, to the
author’s knowledge data on other mitogens has not been published. In the Kyles et al. study,
46nM of cyclosporine was sufficient to cause a 50% reduction in ConA-induced T cell
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proliferation, whereas 33nM of cyclosporine was sufficient to cause a 50% reduction in PMWinduced proliferation, thus suggesting that Con A may be the most suitable activator in cats.
Since PMW stimulates both B and T cells, the exact degree of proliferation of B versus T
lymphocytes was undetermined14. In dogs, phorbol myristate acetate (PMA) and ionomycin are
used as T-cell mitogens in pharmacodynamic monitoring of cyclosporine; however, they have
not been investigated in cats. A protocol for maximal mitogen-induced T cell activation in cats is
required to allow for subsequent pharmacodynamic monitoring of cyclosporine therapy. Thus,
the aims of this experiment were to determine if PMA and ionomycin were suitable for
activation of T lymphocytes in cats and, if successful, to determine appropriate concentrations of
PMA and ionomycin for maximal T-lymphocyte NFAT-regulated cytokine expression and
lymphocyte proliferation.
Materials and Methods
Animals
Twelve client-owned (9 male neutered and 3 female spayed) cats with a mean (± SD)
body weight of 5.18 ± 1.0 kg were used for this study. The following breeds were represented:
domestic shorthair (n=9), domestic longhair (n=2) and Siamese (n=1). Cats were determined to
be healthy based on pre-enrollment physical examination in addition to CBC, serum chemistry
and infectious disease testing. The experimental protocol was approved by the Mississippi State
University Institutional Animal Care and Use Committee (IACUC).
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T-cell Mitogens
Stock solutions of PMA (10 mg/mL) and ionomycin (1mM) from Sigma-Aldrich (St.
Louis, MO) were made in 100% ethanol and were stored at -70°C. Samples were slowly warmed
to 20°C prior to use and were diluted 1:100 in sterile saline for PMA and 1:1 for ionomycin.
Experiment 1 – Whole Blood Collection
For blood collection, each cat was placed on a table and gently restrained in either right
or left lateral recumbency or held sitting with the neck extended. The left or right jugular vein
was clipped and prepped with alcohol. The jugular vein was manually occluded, and a 22-gauge
needle attached to a 10cc syringe was inserted into the jugular vein. 5ml of blood was collected
into heparinized tubes
Experiment 1 – T cell Activation
Half of the sample were activated with PMA and ionomycin at the following
concentrations; PMA 10 ng/mL, 12.5 ng/mL, 15 ng/mL and ionomycin 0.6 µM, 0.8 µM, 1.0 µM
(see Tables 2 and 3), whilst the remaining samples were untreated. Each concentration was
performed in triplicate on each patient. These concentrations were selected based on previous
studies in dogs11. The mixed samples were then incubated at 37°C with 5% CO2 for 5 hours,
based on a previous study9
Experiment 1 – RNA Extraction from Whole Blood
RNA extraction was performed using a commercial RNA extraction kit2 as detailed below;
1. One ml of whole blood was mixed with 5ml of erythrocyte lysis buffer in a 15ml Falcon tube

2

Qiagen RNA Blood Mini Kit, Valencia, CA 91355

45

2. The sample was then incubated on ice for 15 minutes, and vortexed briefly at 5 and 10
minutes
3. The sample was then centrifuged at 400xg for 16 minutes at 4°C, and the supernatant was
discarded
4. Two ml of erythrocyte lysis buffer was then added to the cell pellet and the pellet was
resuspended by vortexing
5. The sample was then centrifuged at 400xg for 16 minutes at 4°C, and the supernatant was
discarded.
6. Six-hundred μL of Buffer RLT® was then added to the pellet
7. The sample was then pipetted onto a QIAshredder® spin column placed inside a 2ml
collection tube
8. The tubes were then centrifuged for 2 minutes at 400xg. The spin column was then
discarded, and the run-through was collected.
9. Six-hundred μL of 70% ethanol was added to the sample. The sample was then placed on a
new QIAamp® spin column.
10. The spin column was then centrifuged at 8000xg for 1 minute and the flow-though was
discarded.
11. Six-hundred μL of sample was then placed onto the same QIAamp® spin column
12. The sample was centrifuged at 8000xg for 1 minute and the flow through was discarded
13. Three hundred and fifty μL of Buffer RW1® was then added to the QIAamp® spin column
14. The sample was then centrifuged at 8000xg for 1 minute and the flow through was discarded
15. Ten μL of DNase stock solution was then added to 70μL of Buffer RDD® immediately prior
to use
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16. The DNase mixture (80μL) was then added to a QIAamp® spin column, and sample was
incubated at room temperature for 15 minutes
17. Three-hunded and fifty μL of buffer RW1® was then added to the QIAamp® spin column
18. The sample was then centrifuged at 8000xg for 1 minute and the flow through was discarded
19. A QIAamp® spin column was then added to a new 2ml collection tube. Five-hundred μL of
buffer RPE® was then added to the QIAamp® spin column
20. The sample was centrifuged at 8000xg for 1 minute and once again the flow through was
discarded
21. Five hundred μL of buffer RPE® was added to a new QIAamp® spin column, and the sample
was centrifuged at 8000xg for 3 minutes and the flow through was discarded.
22. The column was placed in a new 2ml collection tube and was centrifuged at 8000xg for 1
minute
23. The QIAamp® spin column was then transferred to a 1.5ml microcentrifuge tube. Fifty μL of
RNAase free water was then added to the column and centrifuged at 8000xg for 1 minute
24. The samples were stored on ice until RNA quantification
Experiment 2 – Peripheral Blood Mononuclear Cell Isolation
PBMCs were immediately isolated from whole blood by density gradient centrifugation
using Histopaque®-1077, as previously described in dogs15. Following isolation, PBMCs were
reconstituted with an equal volume of complete medium (CM). CM consisted of 9mL of RPMI16403 (Sigma Aldrich, St. Louis, MO) and 1mL of heat-inactivated fetal bovine serum (Atlanta
Biologicals, Flowery Branch, GA). 0.1mL of an antibiotic antimycotic solution (Sigma Aldrich,

3

Sigma Aldrich, St. Louis, MO
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St. Louis, MO) was also added to the culture medium (1000U penicillin, 1mg streptomycin and
2.5mg amphotericin B). PBMC’s were initially utilized to prevent interference from other cell
populations
Experiment 2 – RNA Extraction from PBMC’s
RNA extraction was performed as per the whole blood protocol above, with the exception
of erythrocyte lysis (Buffer EL) steps, which were excluded.
RNA Quantification
RNA quantification was performed using a Thermo Scientific Nano Drop One (Unity
Lab Services, Madison, WI), according to manufacturer instructions. Briefly, 1µl of RNAase free
water (Qiagen, Germantown, MD) was used to calibrate the machine prior to use. 1µl of each
sample was then applied to the reading arm and each sample was recorded in triplicate. If a
greater than 10% difference between results was noted, a fourth reading was performed, and the
discordant data was excluded. A260:A280 ratio of 1.8 – 2.0 indicated no contamination;
however, samples outside of this range were suspected to be contaminated and repeat analysis
was performed on such samples.
PCR Analysis
Feline CsA qPCR Primers
The following NFAT-regulated cytokines were selected for PCR analysis; IL-2, IL-4,
IFN-gamma. GAPDH was used as a housekeeping gene. The primer sequences are listed in
Table 3.1 below and were selected based on a prior study16.
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Table 3.1

Primer sequences for PCR analysis

Primer
IL-2 Forward

Primer Sequence
CGG TTG CTT TTG AAT GGA GTT AA

IL-2 Reverse

TTA AAT GTG AGC ATC CTG GAG AGT T

IL-4 Forward

CGT CTT GGC AGC CCC TAA G

IL-4 Reverse

CGG TTG TGG CTC TGC AGA A

IFN-gamma Forward

AGG AGC ATG GAC ACC ATC AAG

IFN-gamma Reverse

CCC GTT TAC TGG AGC TGG TAT T

GAPDH Forward

AAA TTC CAC GGC ACA GTC AAG

GAPDH Reverse

TGA TGG GCT TTC CAT TGA TGA

Primer sequences for various NFAT-regulated cytokines. GAPDH was used as a housekeeping
gene.
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PCR Settings
Thermal profile settings were adapted from canine studies and from Invitrogen
SuperScript® III Platinum SYBR Green One Step qRT-PCR manufacturer instructions9. The
thermal profile for the PCR analysis was as follows; 50°C for 3 minutes, 95°C for 5 minutes,
followed by 40 cycles of 95°C for 15 seconds and 60°C for 30 seconds, followed by 40°C for 1
minute. Melting curve analysis was performed as followed; 40°C for 1 minute, 95°C for 1
minute, 55°C for 30 seconds and 95°C for 30 seconds.
Data Analysis
The relative change in gene expression of the samples was calculated using the delta CT method
with GAPDH as a reference gene as previously described9. A brief summary is provided below:
1. The ‘reference’ score for each gene was calculated as below;
•

IL-2 Reference Score = Control UNA IL2 – Control ACT IL2

•

IL-4 Reference Score = Control UNA IL2 – Control ACT 1L2

•

IFN-gamma Reference Score = Control UNA IL2 – Control ACT IL2

2. The delta CT value was then calculated as follows;\
•

delta CT for IL-2 = GAPDH CT – IL2 CT

•

delta CT for IL-4 = GAPDH CT – IL4 CT

•

delta CT for IFN-gamma = GAPDH CT – IFN-gamma CT

3. For each patient, the difference between activated (ACT) and unactivated (UNA) CT
values were then calculated for each reference gene as shown below;
•

IL-2 calculated difference = Patient UNA IL2 – Patient ACT IL2

•

IL-4 calculated difference = Patient UNA IL4 – Patient ACT IL4
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•

IFN-gamma calculated difference = Patient UNA IFN-gamma – Patient ACT
IFN-gamma

Results
PMA and ionomycin, at the concentrations documented previously to activate T cells in
dogs, failed to increase total nucleic acid concentration in feline lymphocytes 8. In addition, dose
adjustments in PMA and ionomycin failed to achieve increases in total nucleic acid
concentration. See Table 3.2 and Table 3.3. PCR analysis failed to document a significant
increase in gene expression of the NFAT-regulated cytokines IL-2, IL-4, and IFN-gamma as
determined by delta CT analysis. See Table 3.4
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Table 3.2

Nucleic acid concentrations in unactivated and activated feline samples with the
mitogens PMA and ionomycin at varied concentrations (whole blood).

PMA Concentration
(ng/mL)

Ionomycin Concentration
(µM)

Mean ± SD Nucleic Acid Conc
(ng/µL)

0.0
0.0
2.14 ± 0.32
10.0
0.6
1.30 ± 0.06
10.0
0.8
2.05 ± 0.13
12.5
0.6
1.23 ± 0.17
12.5
0.8
1.62 ± 0.21
12.5
1.0
1.84 ± 0.29
15.0
0.8
1.45 ± 0.04
15.0
1.0
2.16 ± 0.08
The mean concentration of nucleic acid and the standard deviation around the mean are recorded
following RNA extraction from activated feline lymphocytes. The sample used was whole blood.
Incubation with PMA and ionomycin failed to result in consistent detectable increases in nucleic
acid concentration
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Table 3.3

Nucleic acid concentrations in unactivated and activated feline samples with the
mitogens PMA and ionomycin at varied concentrations (PBMCs).

PMA Concentration
(ng/mL)

Ionomycin Concentration
(µM)

Mean ± SD Nucleic Acid Conc
(ng/µL)

0.0
0.0
2.21 ± 0.26
10.0
0.6
1.71 ± 0.34
10.0
0.8
2.02 ± 0.07
12.5
0.6
2.43 ± 0.11
12.5
0.8
1.92 ± 0.10
12.5
1.0
1.82 ± 0.17
15.0
0.8
1.41 ± 0.10
15.0
1.0
2.07 ± 0.14
The mean concentration of nucleic acid and the standard deviation around the mean are recorded
following RNA extraction from activated feline lymphocytes. The sample used was feline
PBMCs. Incubation with PMA and ionomycin failed to result in consistent detectable increases
in nucleic acid concentration.

53

Table 3.4

Change in cytokine expression of NFAT-regulated cytokines following activation
with PMA and ionomycin at varied concentrations.

Cytokine

PMA Concentration
(ng/mL)

Ionomycin Concentration
(µM)

Delta CT

IL-2

10.0

0.6

0.32

IL-2

12.5

0.6

2.62

IL-2

15.0

0.6

0.40

IL-2

10.0

0.8

-2.60

IL-2

12.5

0.8

0.48

IL-2

15.0

0.8

0.61

IL-2

10.0

1.0

0.34

IL-2

12.5

1.0

-3.20

IL-2

15.0

1.0

-4.26

IL-4

10.0

0.6

0.22

IL-4

12.5

0.6

-4.70

IL-4

15.0

0.6

0.32

IL-4

10.0

0.8

-2.60

IL-4

12.5

0.8

0.48

IL-4

15.0

0.8

-2.11

IL-4

12.5

1.0

-0.01

IL-4

15.0

1.0

-4.26

IFN-γ

10.0

0.6

-0.12

IFN-γ

10.0

0.8

-3.86

IFN-γ

12.5

0.6

-5.14

Incubation with PMA and ionomycin failed to result in significant detectable increases in
expression of various NFAT regulated cytokines
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Discussion
In this study, we documented that PMA and ionomycin at the following concentrations;
PMA 10.0-15.0 ng/mL and ionomycin 0.0-1.0µM, appeared to fail to sufficiently activate feline
lymphocytes in whole blood or isolated PBMCs, as determined by RNA quantification and PCR
analysis in unactivated and activated samples. In dogs, PMA at 12.5 ng/mL and ionomycin at 0.8
µM are frequently used for T-lymphocyte stimulation8,9,17
Potential explanations for the failure of PMA and ionomycin to detectably activate feline
T lymphocytes in this study include species differences in response to mitogens, the use of
insufficient doses of mitogen and the use of inappropriate incubation conditions. PMA,
ionomycin and ConA have different mechanisms of action, and this may help to explain species
differences in response to each mitogen. PMA activates protein kinase C, whereas ionomycin
increases intracellular calcium concentration, both of which ultimately result in T-lymphocyte
stimulation18,19. Interestingly, previous studies in cats have uniformly utilized the mitogens
ConA or pokeweed, and unpublished preliminary studies by Kyles et al. suggest that ConA and
pokeweed are the most successful T lymphocyte activators in cats12,13. ConA has a direct effect
on the T-cell receptor leading to down-stream signal transduction20. Pokeweed, in contrast to
ConA, has been shown to stimulate both B and T lymphocytes in humans14. Further potential
explanations include failure to detect the amplified RNA sequence. This can relate to failure of
the primer sequences to anneal to the target RNA strand. The primers selected; however, had
previously been used successfully in a feline qRT-PCR study16, thus promoting consideration of
technological issues. Potential technical issues include an inadequate annealing temperature or
annealing time. Additional potential considerations include the presence of introns between
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primer sites resulting in incomplete product or failure to amplify, and hair-pinning of primers
due to compatible sequences with each primer.
Future studies should evaluate the primer sequences utilized in this study to determine
whether the mitogens utilized failed to activate T lymphocytes, or whether the study failed due to
inability to detect amplified RNA sequences. Future studies should also investigate a dose
titration of other mitogens, such as ConA or pokeweed, for maximal stimulation of feline
lymphocytes. The ultimate long-term goal would be to generate a commercially available tool for
pharmacodynamic monitoring of cyclosporine in cats.
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2. Concanavalin A Titration Using Flow Cytometry
Introduction
Con A is a T-lymphocyte mitogen commonly utilized in cats, and its mechanism of
action is via direct stimulation of the T-lymphocyte receptor12,13,20. However, dose optimization
is required to maximize T-lymphocyte stimulation in vitro. In this brief study, we utilized flow
cytometry to determine the most suitable concentration of Con A for stimulation of feline
PBMCs.
Materials and Methods
Animals
Two client-owned (both female spayed) cats with a mean (± SD) body weight of 4.4 ±
0.71 kg were used for this study. Both cats were of the domestic shorthair breed. Cats were
determined to be healthy based on pre-enrollment physical examination in addition to CBC,
serum chemistry and infectious disease testing. The experimental protocol was approved by the
Mississippi State University Institutional Animal Care and Use Committee (IACUC).
Incubation and Activation Protocols
Serial dilutions of Con A (Sigma Aldrich, St. Louis, MO) were produced via dilution
with CM. CM was formulated as documented in the previous experiment. The following
concentrations of ConA were produced: 20µg/mL, 10µg/mL, 5µg/mL, 2.5µg/mL, and
1.25µg/mL. A negative control consisting of CM was also utilized. The concentrations were
selected due to prior successful use of 5µg/mL16.
PBMCs were isolated as documented in the previous experiment. PBMC’s were then
incubated with the following concentrations of ConA: 0µg/mL (control), 1.25µg/mL, 2.5µg/mL,
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5µg/mL, 10µg/mL and 20µg/mL. The incubation conditions were as follows: 37°C and 5% CO2
and 10 hours of incubation.
Flow Cytometry
After incubation, 2mL of suspension from each well was transferred into flow cytometric
tubes (Sigma Aldrich, St. Louis, MO). The sample was then centrifuged at 500xg for 5 minutes.
The supernatant was decanted into a waste receptacle and the sample was washed with 2mL of
PBS. This process was repeated twice. 3µL of LIVE/DEAD fixable dead cell stain was then
added to the sample, and the sample was vortexed lightly to mix the contents. The sample was
then incubated for 30 minutes at room temperature. The sample was then centrifuged at 500xg
for 5 minutes, and the supernatant was decanted. The sample was then washed with PBS as
above. Finally, the sample was re-suspended in complete media and passed through a 35-micron
filter to remove any clot material. The material was then analyzed by flow cytometry using the
following lasers/filters;
•

405nm laser with the 530/30 bandpass filter (LIVE/DEAD aqua)

•

Threshold = 300,000 cells

•

Collect = 25,000 cells

•

V Channel 2

•

Slow setting

Results
The samples from both cats incubated with 20µg/mL ConA visibly clotted, likely
indicating cell death. These samples were not submitted for flow cytometry analysis to prevent
inadvertent damage to the machine. Analysis of flow cytometry data revealed that 5µg/mL and
58

10µg/mL ConA had similar activation, but 10µg/mL ConA had lower viability. Cat two had an
abnormal scatter pattern and was excluded from analysis.
Discussion
Flow cytometry was utilized to assess PBMC activation in response to ConA stimulation.
Our study found that 5µg/mL of ConA was the most suitable choice for PBMC activation in cats.
This dose is the same as in a previous study16.
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CHAPTER IV
CONCLUSIONS AND FUTURE WORK
This thesis details the initial investigations and groundwork required for further studies
into pharmacodynamic monitoring of cyclosporine therapy in cats. Our research initially
evaluated PMA and ionomycin as T-cell mitogens, given their success in canine
pharmacodynamic assays. However, PMA and ionomycin at various concentrations failed to
provide sufficient activation of T lymphocytes and were therefore not suitable for subsequent
analysis with cytokine primers. We subsequently turned our attentions to ConA as a potential T
cell mitogen. Our initial experiment evaluated titrations of ConA, with evaluated concentrations
centered around a previously published concentration, and the data supported the use of 5µg/mL
of ConA for T-lymphocyte activation in cats. This concentration of ConA was subsequently used
to stimulate PBMCs as part of a cell proliferation study, in which feline PBMCs were quantified
daily for 6 days, via trypan blue exclusion dye. Alive and necrotic cell counts were performed on
cell cultures exposed to Con A and cyclosporine. This study documented an optimal activation
time of 5 days for cyclosporine in cats, much longer than previously published1. This study also
confirmed the findings of a previous study, and documented cyclosporine’s anti-lymphocytic
properties in cats. The results of the above in vitro studies when considered in unison suggest a
suitable activation protocol for T lymphocytes in cats would comprise of 5% C02 with a 5-day
incubation time with 5µg/mL ConA. This protocol may provide a basis for future
pharmacodynamic studies evaluating lymphocytes in cats. Future studies should utilize the above
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activation protocol to evaluate expression of NFAT-regulated cytokines, and their response to
cyclosporine therapy.
Preliminary studies as part of this project investigated measurement of IL-2, IL-4, IFNgamma and the housekeeping enzyme GAPDH (nucleotide sequences listed in Table 4) using a
quantitative reverse transcription PCR as documented by Kuga et al1. However, in our study,
detection of cytokines was unsuccessful. Potential explanations for this include the presence of
introns between primer sites resulting in incomplete product and failure to amplify, hair-pinning
of primers due to compatible sequences within each primer or primer-dimerization, and
potentially incompatible PCR parameters2. However ,the PCR parameters utilized in our study
were based on the previously successful work by Kuga et al1.
Given the failure of pharmacokinetic monitoring tools to correlate with clinical
immunosuppression, and the lack of consensus regarding therapeutic cyclosporine blood levels,
pharmacodynamic monitoring offers much promise in feline medicine3,4. Following the
development of an optimal T lymphocyte activation protocol as part of this research, and prior
documentation of successful measurement of NFAT-regulated cytokines via PCR in cats1, a
PCR-based technique probably offers the most promise in the development of a commercial
pharmacodynamic monitoring tool for cyclosporine in cats. However, further optimization and
validation of a quantitative reverse transcription PCR for measurement of various NFATregulated cytokines in cats is required prior to commercial utilization. Transition to a whole
blood-based assay is also likely indicated prior to commercial use
Pharmacodynamic monitoring techniques would not only assist in the management of
individual patients, but could also be used to investigate suitable starting doses of cyclosporine
for systemic immunosuppression in cats. The current lack of consensus on the ideal dose of
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cyclosporine for systemic immunosuppression in cats is clear when evaluating prior studies.
Starting dose ranges of 5-20mg/kg/day have been documented, with a dose frequency of either
every 12 hours or every 24 hours5–13. In dogs suffering from acute life-threatening immunemediated disease, a dosage of 5-10mg/kg PO q 12h is recommended, whereas a dosage of
5mg/kg PO q 24h is recommended for most dermatological indications14. It is likely that twice
daily administration of cyclosporine is also required in cats for systemic immunosuppression,
given prior reports; however, additional research is required to confirm these anecdotal
suspicions and small case reports.
Although not studied here, additional research areas for pharmacodynamic monitoring of
cyclosporine in cats may include assessment of proliferation assays, surface antigens as markers
of T cell activation and calcineurin inhibition assays, as previously studied in dogs and humans
Cyclosporine has been shown to induce apoptosis in human mitogen-activated PBMC’s;
however, this had not previously been studied in cats15. During this project, we investigated the
effects of cyclosporine on lymphocyte apoptosis. To our knowledge, this is the first project to
document lymphocyte apoptosis associated with cyclosporine therapy in cats. We utilized an
Annexin-V apoptosis detection kit (BioVision Inc, Mountain View, CA) as previously
described16 and noted both early and late apoptotic change in feline PBMC’s. Although
definitive conclusions are limited by animal numbers, we also documented marked individual
variation in the apoptotic response of PBMCs to cyclosporine. This may help explain variations
in individual patient responses to cyclosporine. Future studies should evaluate apoptotic
responses of PBMCs to cyclosporine in a larger group of cats. If marked variation is noted, in
vivo assessment of apoptosis and its correlation with clinical immunosuppression should be
considered; however, the use of flow cytometry, which is too cumbersome for routine clinical
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use, to assess apoptosis limits the commercial application of apoptotic monitoring of
cyclosporine therapy in cats.
Although pharmacokinetic monitoring of cyclosporine is not recommended when treating skin
disease17, veterinarians should remain vigilant to marked unpredictable immunosuppression in
individual patients. If patients appear to be overtly immunosuppressed, it is the author’s opinion
that measurement of peak or trough cyclosporine blood levels should be considered until further
pharmacodynamic monitoring tools are developed. However, if the results of pharmacokinetic
monitoring do not correlate with clinical suspicion, veterinarians should consider the previously
documented limitations with such techniques in cats.
This thesis describes preliminary studies into pharmacodynamic monitoring of
cyclosporine in cats and, with further investigation, pharmacodynamic monitoring may become a
commonly utilized tool in the balance between maintaining sufficient immunosuppression and
avoidance of life-threatening secondary infections such as toxoplasmosis in cats receiving
immunosuppressive doses of cyclosporine.
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